A Mini-Symposium: Implementing Precision and Equitable Public Health in Cascade Testing for Genetic Disorders
February 10, 2022, 1:00 pm -3:00 pm ET
While there are Tier 1 evidence-based guidelines supporting cascade testing for hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial hypercholesterolemia, and other genetic disorders, the focus is on whether such testing should be done, rather than how to implement cascade testing in practice, both effectively and equitably. Before the full potential health impact of cascade genetic testing can be reached, we must develop a much stronger understanding of which component procedures and practices work best, and then leverage those good practices toward delivering precision public health.
This two-hour virtual mini-symposium will explore several efforts to better understand what works well in programs relevant to cascade testing for genetic disorders. Presentations will be 20 minutes each, followed by a brief period for discussion and questions from the audience.
Chanita Hughes-Halbert, PhD
Vice Chair for Research and Professor, Department of Population and Public Health Sciences
Associate Director for Cancer Equity, Norris Comprehensive Cancer Center
University of Southern California
Megan Roberts, PhD
Director, Implementation Science in Precision Health & Society,
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill,
Chapel Hill, NC
Angela Bedard, MS, CGC
Kasmintan Schrader, MBBS, FRCPC, PhD, DABMG
Program Medical Co-Director Hereditary Cancer,
Alanna Kulchak Rahm, PhD, MS, CGC
Dissemination and Implementation,
Genomic Medicine Institute,
Laura Senier, PhD, MPH
Department of Sociology and Anthropology
and Department of Health Sciences,
Nora B. Henrikson, PhD, MPH
Kaiser Permanente Washington Health Research Institute,
- Roberts MC, et al. 2018. Delivery of Cascade Screening for Hereditary Conditions: A Scoping Review of the Literatureexternal icon. Health Affairs (Millwood) 37(5):801-808.
- Braley, EF, et al. 2021. Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer programexternal icon. Familial Cancer Jul 7, online ahead of print.
- Di Nucci A, et al. 2021. Feasibility and Assessment of a Cascade Traceback Screening Program (FACTS): Protocol for a Multisite Study to Implement and Assess an Ovarian Cancer Traceback Cascade Testing Program. Journal of Personalized Medicine 11(6):543.
- Senier L, et al. 2019. Blending Insights from Implementation Science and the Social Sciences to Mitigate Inequities in Screening for Hereditary Cancer Syndromesexternal icon. International Journal of Environmental Research and Public Health 16(20):3899.
- Henrikson NM, et al. 2020. What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?external icon Journal of Law and the Biosciences 7(1):1-14.
- Office of Genomics and Precision Public Health, Office of Science